Characterizes the mitochondrial targeting protein in Strongyloides ratti, suggesting potential for drug design strategies.
Strongyloides ratti is widely used as an experimental model for studying and diagnosing humans strongyloidiasis. The alpha/beta hydrolase domain proteins are ubiquitously distributed across all organisms. In this study, a 780-nucleotide cDNA fragment was amplified by RT-PCR, and BLAST analysis revealed that 98.54% sequence identity with the only incomplete S. ratti mRNA sequence available in GenBank (XM_024652394.1). Using this fragment as a probe, two expressed sequence tags (ESTs), 856 bp (FC815910.1) and 526 bp (BI742498.1), corresponding to the 3'and 5' ends, respectively, were identified and assembled into a full length cDNA of 919 bp, designated SrABH. Its amino acid sequence exhibited 97.98% identity with the only available S. ratti sequence in GenBank (XP_024505975.1). The molecular weight (MW) and isoelectric point (pI) of the protein are 33.484 kDa and 7.18, respectively. Signal peptide analysis indicated the absence of a secretion signal, however a mitochondrial targeting cleavage site was identified between amino acids 21-22. The highly conserved motif consists of nine amino acids spanning positions 111 to 120. The 3D structural analysis revealed that SrABH consists of 9 alpha-helices (39.18%), 8 beta-sheets (18.21%), and loop regions (42.61%). Phylogenetic analysis clustered SrABH with related nematode sequences, displaying by a high bootstrap support of 98. The lowest genetic distance (0.01%) was observed between SrABH and the only sequence isolated from S. ratti (XP_024505975.1). Given its molecular characteristics, this parasite’s data may be valuable in structure-based drug design strategies using S. ratti as a model system for the human pathogen S. stercoralis.
No takes yet. Share an insight, caveat, or question.
Abbas Jolodar (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: